I framed the current phase as an opportunity to refine our strategy, strengthen our foundation, and ensure that every move we make is sharper and impactful in the long run.
I described Q3 as another step in our journey to shape Honasa into a powerhouse of brands that shape the future of India’s beauty and personal care landscape.
I reported Q3FY25 revenue of ₹518 Cr, reflecting 6.0% YoY growth, with an EBITDA margin of 5.0%.
I reported first-nine-month FY25 revenue of ₹1,533 Cr, marking 5.8% YoY growth while revenue when adjusted for one-time inventory correction in Q2FY25 stood at ₹1,596 Cr with 10.2% YoY growth.
I said Mamaearth was present in over 2 lakh offline outlets across India, as per NielsenIQ.
According to Kantar's Brand Health Track, Mamaearth was perceived as #1 brand in online and #3 in offline in the face wash category in terms of Brand Power/Equity.
I said our emerging brands, The Derma Co., Aqualogica, BBlunt, and Dr. Sheth's, were delivering over 30% YoY growth.
I reported that our key categories recorded approximately 18% growth in 9MFY25, adjusted for the Q2FY25 inventory correction.
I reported that quick-commerce was growing over 200% YoY in 9MFY25, as consumers increasingly preferred receiving Honasa products in under 10 minutes.
- I said our priorities were driving innovation, deepening offline expansion, and strengthening category leadership.
I said we are building Honasa like a flywheel, where initial rotations take everything you've got but eventually become self-sustaining.
I reported ₹682 Cr in revenue; 28% YoY growth for Q4.
I reported that EBITDA doubled; PAT more than doubled to ₹69 Cr.
I reported three consecutive quarters of 20%+ growth; every metric is at its highest ever.
I said Mamaearth was gaining share in key categories, with Ubtan and Onion growing 2x faster than the brand and Rice Face Wash and Rosemary Shampoo scaling hard behind them.
I reported that The Derma Co. was at its strongest quarter ever with double-digit EBITDA.
I reported that younger brands were up 40%+ in FY26.
I reported Reginald Men—₹100 Cr ARR in its very first quarter with us.
I announced our first-ever dividend, approved by the board—₹3 per share.
In February 2025, I described a phase of strategic refinement and foundation-building, with innovation, offline expansion, and category leadership as priorities. By May 2026, I described Honasa’s growth through a flywheel metaphor and highlighted stronger company and brand performance. The February post also thanked consumers, partners, and the team for their trust and continued support.
I have shared Honasa’s financial and operating results across several reporting periods. These posts describe growth, profitability, brand milestones, distribution, operational efficiency, and company initiatives; the announcements do not provide all underlying definitions or calculations.
In my Q2 results announcement, I reported that Honasa grew 33% for H1 and grew profits by 14X over last year H1 to 54 Cr.
I described Honasa as capital efficient, citing negative working capital and highest gross margins in industry while showcasing leverage and efficiency on A&P spends.
I announced that Mamaearth entered the top 15 BPC brands club, overtaking many legacy brands.
I announced that Dr Sheth became the 4th Honasa brand to enter 150 Cr ARR club.
I said Honasa continued planting more trees, recycling more plastic, providing more education and protecting the environment while remaining strong on our governance frameworks.
In my Q3FY24 results announcement, I reported revenue growth of 27.8% YoY.
I reported Q3FY24 EBITDA of INR 34.5 Cr. (192% YoY growth).
I reported Q3FY24 PAT of INR 26 Cr. (263.5% YoY growth).
I reported negative working capital of minus 6 days in Q3FY24.
I said Mamaearth color cosmetics had reached INR 150 Cr.+ ARR and had sold over 10 lacs color care units in Q3FY24.
I reported that Mamaearth Rosemary hair care became INR 50+Cr. in just 6 months of launch.
I reported over ~1.7 Lacs retail touch points increasing distribution by 37% YoY for Honasa’s omnichannel distribution.
I announced that The Derma Co. became EBITDA profitable.
For Q4, I reported 23% (like-for-like) YoY revenue growth for Honasa Consumer.
I reported full year PAT of INR 111 Cr.
I reported 7.1% EBITDA for the full year.
I reported that Honasa delivered ever-highest quarterly PAT of INR 30 Cr.
I reported 120 bps offline market-share growth YoY for facewashes for Mamaearth.
I reported 40 bps for shampoos as Mamaearth’s offline market-share growth YoY.
I announced that The Derma Co hits INR 500 Cr+ ARR.
I reported that The Derma Co. achieved break-even in all quarters of FY24.
I announced the acquisition of Cosmogenesis laboratories to strengthen Honasa's R&D capabilities.
I said the formulation experience we added was built through 5000+ formulations over 25+ years of experience.
I announced that Honasa launched its first impact assessment report, highlighting economic value generation, student engagement, and women-focused interventions delivered across brands.
In my Q1 FY25 results announcement, I reported consolidated revenue surging to INR 554 CRORE.
My announcement stated “62.9% PAT and 19.3% growth YOY,” without making clear what the growth figure refers to or what “62.9% PAT” denotes.
I reported that the face wash category achieved approximately INR 800 crore GMV ARR for Honasa.
I reported that Mamaearth reached nearly 2 lakh FMCG retail outlets in India as of June'24, with distribution increasing by 30% YoY.
I reported that new products accounted for around 9% of Q1FY25 Revenue from Operations.
I said Honasa maintained negative working capital cycle.
Across these announcements, I reported company and brand results alongside operating and impact initiatives. The posts do not give detailed definitions or supporting calculations for several metrics, identify the FMCG peers and legacy brands used in comparisons, or specify acquisition terms and quantified R&D impact.
Related: profitable consumer brand growth, brand portfolio expansion, product innovation and quality